Affimed to Present at Jefferies Virtual Cell Therapy Summit
Heidelberg, Germany, September 29, 2020 – Affimed N.V.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Heidelberg, Germany, September 29, 2020 – Affimed N.V. (Nasdaq: AFMD) announced its presentation at the Jefferies Virtual Cell Therapy Conference on October 6 at 8:00 a.m. Eastern Time. The event's live webcast will be accessible via the “Investors” section on Affimed’s website and will remain available for 30 days post-event. Affimed focuses on innovative immuno-oncology treatments, leveraging its ROCK® platform for tailored therapies aimed at hematologic and solid tumors. The company is currently advancing studies on AFM13 and AFM24.
Details
News Market Reaction – AFMD
The recorded move for AFMD in the trading session of this news was +3.01%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Heidelberg, Germany, September 29, 2020 – Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced that the company’s management will present at the Jefferies Virtual Cell Therapy Conference on Tuesday, October 6 at 8:00 a.m. Eastern Time.
A live webcast of the presentation can be accessed under the “Investors” section of Affimed’s website at https://www.affimed.com/investors/webcasts_cp/ and will be available for 30 days following the event.
About Affimed N.V.
Affimed (Nasdaq: AFMD) is a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer. Affimed’s fit-for-purpose ROCK® platform allows innate cell engagers to be designed for specific patient populations. The company is developing single and combination therapies to treat hematologic and solid tumors. The company is currently enrolling patients into a registration-directed study of AFM13 for CD30+ relapsed/refractory peripheral T cell lymphoma and into a Phase 1/2a dose escalation/expansion study of AFM24 for the treatment of advanced EGFR-expressing solid tumors. For more information, please visit www.affimed.com.
Affimed Investor Contact
Alexander Fudukidis
Head of Investor Relations
E-Mail: a.fudukidis@affimed.com
Tel.: (917) 436-8102
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.